Ceetox sees increase in EU interest since sweeping ban

The organisation dedicated to the development of alternative methods for the industry have noted a major increase in interest from the EU on in vitro toxicity screening options since the sweeping ban came into force last month.

CosmeticsDesign-Europe.com caught up with the US based company which was exhibiting at in-cosmetics last week, where sales & marketing director Syed Ahmed Mustafa revealed that their booth had been inundated with brands wanting to know how to validate and develop internal data sets that will accurately predict the safety of a finished product as well as its ingredients.

Influx in demand for the company

Despite testing cosmetics on animals being banned in Europe since 2009; the final sweeping ban on the 11th of March marked the day that some in the industry thought would be further delayed, thus prompting those yet to seek out alternative testing, rushing to catch up.

Mustafa says that for Ceetox, getting the message across on toxicity testing alternatives has been a hard feat due to the intial delay of the ban, but that from being at the show this year, the reaction from the industry has definitely changed.

"In my opinion, as 2013 rolled around, most companies reckoned that the EU wouldn’t have the methods in place and that the deadline would be delayed. Now that is has, companies are being faced with how to meet it, and some are seeking out the most efficient concept."

5 step strategies

The marketing and sales director says that in this instance they have been advising cosmetic professionals to opt for testing strategies such as its CeeTox Cosmetics Products Panel or ‘C2P2’.

The panel, the company says is a first in offering cosmetic finished goods and ingredients manufacturers a fast and affordable way to assess the risk in finished products and can determine ocular, dermal and airway irritation, dermal sensitization and photosensitization all within a six week period.

The test uses a systems biology approach that focuses on multiple biochemical endpoints, over a wide range of exposure concentrations. By building a temporal component into the analysis, it is possible to identify the most sensitive subcellular target of toxicity.